Optimize Site Selection & Patient Enrollment

To identify potential KOL partners, Innoplexus’ KOL Discovery Platform assesses, segments, and prioritizes KOLs by leveraging the information found across numerous types of data sources (assets). Our AI has aggregated 20 million researcher and physician profiles across most countries globally.
For further stratification, KOLs can be segmented into four buckets based on their activities; thought leader, speaker, scientific, commercial, and additionally into emerging and top KOLs. Users are able to analyze KOL’s involvement across all asset classes and customize their KOL scoring criteria based on various filterable and weighable data sources ranked according to client preference – filter them by therapeutic area, location, publications, clinical trials, relationships with pharmaceutical competitors, and numerous customizable filters.
Access untapped KOL networks.

Clinical research organizations often face short timelines for performing trial feasibility and costing studies for proposals from sponsors. Innoplexus AI technology optimizes and expedites clinical trials via network analyses that unsilo, structure, and connect diverse data points across the clinical trial landscape.
Real-time data-driven insights drawn from millions of relevant data points empower clinical trial coordinators to identify centers of untapped patient populations, discover emerging and underutilized KOLs, and locate KOLs with specific expertise (e.g., rare/orphan disease).
Identify and select clinical trial sites based on site’s involvement in past trials by drug phase and indication, number of associated scientific KOL, proximity to patient populations, and hospital features (departments present, hospital beds, etc.).